While U.S.
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with America’s Choice Provider Network …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that the U.S.
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and nine months ended September 30, …
Trovagene, Inc. (NASDAQ:TROV), a leading enterprise software company for brand advertising, announced the launch of its new cross-screen planning technology.
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, today announced the presentation of clinical data featuring the use of its Precision Cancer Monitoring℠ …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today the presentation of clinical results featuring the use of its Precision Cancer Monitoring℠ …
Maxim’s healthcare analyst Jason Kolbert came out with a positive commentary on TrovaGene Inc (NASDAQ:TROV), following the news that the company’s urine-based HPV HR Test is equally capable of detecting …
In a research report published yesterday, Cantor analyst Bryan Brokmeier initiated coverage on shares of TrovaGene Inc (NASDAQ:TROV) with a Buy rating and price …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today the establishment of Trovagene Research Institute (TRI), a European subsidiary focused on expanding …
